Recent Updates
Recently added Catalysts
WHWK Positive Sentiment

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Key Takeaway: Whitehawk Therapeutics, a clinical-stage oncology company, announced that its President and CEO, Dave Lennon, will present at the Jefferies 2026 Global Healthcare Conference on June 4. The presentation will focus on the company's innovative antibody drug conjugate (ADC) treatments. A live webcast of the event will be available for 30 days post-presentation.
Price reaction · baseline $4.78 (2026-05-27 close) · hit after-hours · 1 other WHWK headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Whitehawk Therapeutics is advancing oncology treatments.
  • The company has a strong ADC portfolio aimed at difficult cancers.
  • Presentation at a major healthcare conference increases visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~38 mo
Minimal dilution risk
Lead asset
HWK-016, MUCIN-16-targeted ADC
Phase 1 · PROC

Full Press Release Details

MORRISTOWN, N.J.,May 28, 2026/PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IRwebsiteand will be available for replay for approximately 30 days following the event.
About Whitehawk TherapeuticsWhitehawkTherapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments.Whitehawk'sadvanced three-assetADCportfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed fromWuXiBiologics under an exclusive development and global commercialization agreement. More information on the Company is available atwww.whitehawktx.comand connect with us on LinkedIn.

Contact:[email protected]

Frequently Asked Questions

When will Whitehawk Therapeutics present at the conference?

Whitehawk Therapeutics will present on June 4 at 8:10 AM ET.

Where can I watch the Whitehawk presentation?

The presentation will be available via a live webcast on their IR website.

What is the focus of Whitehawk's presentation?

The presentation will highlight their advanced antibody drug conjugate cancer treatments.

Who is presenting for Whitehawk Therapeutics?

Dave Lennon, PhD, President and CEO, will be presenting.

Last updated: May 28, 2026